Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | SUCNR1 | Q9BXA5 | 11/20 | 0.33 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
| ▸ | SCD | O00767 | 1/20 | 0.31 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.31 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.31 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.31 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20566636 | 1.00 | GSK3B (0.34) | GSK3BDYRK1ASUCNR1SERPINE1AR | |
| SCHEMBL29358093 | 0.94 | SERPINE1 (0.35) | GSK3BDYRK1ASUCNR1SERPINE1AR | |
| SCHEMBL20566411 | 0.89 | SERPINE1 (0.35) | GSK3BDYRK1ASUCNR1SERPINE1AR | |
| SCHEMBL20566410 | 0.89 | SERPINE1 (0.35) | GSK3BDYRK1ASUCNR1SERPINE1AR | |
| SCHEMBL20566413 | 0.89 | SERPINE1 (0.35) | GSK3BDYRK1ASUCNR1SERPINE1AR | |
| SCHEMBL20566536 | 0.89 | MMP2 (0.33) | SUCNR1FFAR4SCDNAMPT | |
| SCHEMBL20566534 | 0.89 | MMP2 (0.33) | SUCNR1FFAR4SCDNAMPT | |
| SCHEMBL20566293 | 0.85 | POLB (0.32) | SERPINE1PCSK9FFAR4NAMPT | |
| SCHEMBL29357614 | 0.85 | POLB (0.32) | SERPINE1PCSK9FFAR4NAMPT | |
| SCHEMBL18991650 | 0.81 | ALOX5AP (0.33) | SERPINE1SCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11230543-B2 | Biaryl monobactam compounds and methods of use thereof for the treatment of bacterial infections | MERCK SHARP & DOHME CORP. (US) | 2022-01-25 | — | — | US | disclosed |
| US-20200361928-A1 | BIARYL MONOBACTAM COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF BACTERIAL INFECTIONS | MERCK SHARP & DOHME CORP. (US) | 2020-11-19 | — | — | US | disclosed |
| US-20180339983-A1 | BIARYL MONOBACTAM COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF BACTERIAL INFECTIONS | MERCK SHARP & DOHME CORP. (US) | 2018-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180339983-A1 | BIARYL MONOBACTAM COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF BACTERIAL INFECTIONS | BMX, BTK, ABCB11 | GSK3B 18/4885DYRK1A 311/4885SUCNR1 2417/4885 |
| US-11230543-B2 | Biaryl monobactam compounds and methods of use thereof for the treatment of bacterial infections | SQLE, ABCB11, BMX | GSK3B 15/4885DYRK1A 285/4885SUCNR1 2659/4885 |
| US-20200361928-A1 | BIARYL MONOBACTAM COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF BACTERIAL INFECTIONS | ABCB11, SQLE, BMX | GSK3B 24/4885DYRK1A 290/4885SUCNR1 2712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.